Incyte | INCY - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Acadia Pharmaceuticals USD 46.47M 42.49M 2026-06
Agenus USD 39.21M 49.82M 2026-03
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
Amgen USD 2.08B 570M 2026-03
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Biogen USD 647.3M 269.6M 2026-06
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Eli Lilly USD 8.85B 583.8M 2026-03
Exelixis USD 262.68M 5.01M 2026-06
Gilead Sciences USD -7.53B 10.11B 2026-06
Incyte USD 751.51M 407.91M 2026-06
Ionis Pharmaceuticals USD -114M 21M 2026-06
MacroGenics USD -36.77M 21.84M 2026-03
Merck USD -3.53B 6.95B 2026-03
Moderna USD -1.33B 535M 2026-03
Nektar Therapeutics USD -43.09M 8.39M 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novartis USD 4.27B 430M 2026-06
Novartis USD 3.84B 1.33B 2026-03
Pfizer USD -653M 5.84B 2026-06
PTC Therapeutics USD -2.46M 136.62M 2026-03
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.53B 696.6M 2026-06
Sarepta Therapeutics USD -1.75M 344.92M 2026-06
Ultragenyx Pharmaceutical USD -91M 93M 2026-06
Vertex Pharmaceuticals USD 1.39B 138.9M 2026-06